References

References1.Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69–e171.RosamondW]]FlegalK]]FridayG&etal;American Heart Association Statistics CommitteeStroke Statistics SubcommitteeHeart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation2007115e69-e1712.Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–952.YusufS]]HawkenS]]OunpuuS&etal;INTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.Lancet2004364937-9523.National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation20021063143-34214.Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.GrundySM]]CleemanJI]]MerzCN&etal;National Heart, Lung, and Blood InstituteAmerican College of Cardiology FoundationAmerican Heart AssociationImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation2004110227-2395.Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.CannonCP]]BraunwaldE]]McCabeCH&etal;Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med20043501495-15046.Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823–2828.StamlerJ]]WentworthD]]NeatonJDIs relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).JAMA19862562823-28287.Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301–1310.BarterP]]GottoAM]]LaRosaJC&etal;Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.N Engl J Med20073571301-13108.Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–2445.PedersenTR]]FaergemanO]]KasteleinJJ&etal;Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.JAMA20052942437-24459.Koro CE, Bowlin SJ, Stump TE, et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151:755.e1–755.e6.KoroCE]]BowlinSJ]]StumpTE&etal;The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.Am Heart J2006151755.e1-755.e610.Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2:485–501.BaysHEExtended-release niacin/lovastatin: the first combination product for dyslipidemia.Expert Rev Cardiovasc Ther20042485-50111.Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2002;2:325–333.Abdel-MaksoudMF]]HokansonJEThe complex role of triglycerides in cardiovascular disease.Semin Vasc Med20022325-33312.Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98:1363–1368.LiuJ]]SemposCT]]DonahueRP&etal;Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.Am J Cardiol2006981363-136813.Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413–1419.CuiY]]BlumenthalRS]]FlawsJA&etal;Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.Arch Intern Med20011611413-141914.Robinson JG, Wang S, Smith BJ, et al. Meta-Analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease. J Am Coll Cardiol 2009;53:316–322.RobinsonJG]]WangS]]SmithBJ&etal;Meta-Analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease.J Am Coll Cardiol200953316-32215.Davidson MH, Stein EA, Bays HE, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354–1367.DavidsonMH]]SteinEA]]BaysHE&etal;COMBination of prescription Omega-3 with Simvastatin (COMBOS) InvestigatorsEfficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.Clin Ther2007291354-136716.Hokanson JE. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep 2002;4:488–493.HokansonJEHypertriglyceridemia and risk of coronary heart disease.Curr Cardiol Rep20024488-49317.Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006;1:389–420.BaysH]]BallantyneCAdiposopathy: why do adiposity and obesity cause metabolic disease?Future Lipidol20061389-42018.Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753–1762.DavidsonMH]]RobinsonJGSafety of aggressive lipid management.J Am Coll Cardiol2007491753-176219.Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106–107.RobertsWCThe rule of 5 and the rule of 7 in lipid-lowering by statin drugs.Am J Cardiol199780106-10720.Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005;59:456–463.Van GanseE]]SouchetT]]LaforestL&etal;Ineffectiveness of lipid-lowering therapy in primary care.Br J Clin Pharmacol200559456-46321.Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol 2006;97:6C–26C.BaysHStatin safety: an overview and assessment of the data—2005.Am J Cardiol2006976C-26C22.Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090–1098.YokoyamaM]]OrigasaH]]MatsuzakiM&etal;Japan EPA Lipid Intervention Study (JELIS) InvestigatorsEffects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.Lancet20073691090-109823.Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23:B49–B53.SteinerGLipid intervention trials in diabetes.Diabetes Care200023B49-B5324.Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.BlankenhornDH]]NessimSA]]JohnsonRL&etal;Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA19872573233-324025.Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264:3013–3017.Cashin-HemphillL]]MackWJ]]PogodaJM&etal;Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up.JAMA19902643013-301726.Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007–3012.KaneJP]]MalloyMJ]]PortsTA&etal;Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.JAMA19902643007-301227.Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–1592.BrownBG]]ZhaoXQ]]ChaitA&etal;Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med20013451583-159228.Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405–418.CarlsonLA]]RosenhamerGReduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand1988223405-41829.Bays H, Stein EA. Pharmacotherapy for dyslipidaemia—current therapies and future agents. Expert Opin Pharmacother 2003;4:1901–1938.BaysH]]SteinEAPharmacotherapy for dyslipidaemia—current therapies and future agents.Expert Opin Pharmacother200341901-193830.Harper CR, Jacobson TA. An evidence-based approach to the use of combination drug therapy for mixed dyslipidemia. JCOM 2006;13:57.HarperCR]]JacobsonTAAn evidence-based approach to the use of combination drug therapy for mixed dyslipidemia.JCOM2006135731.Merck/Schering-Plough Pharmaceuticals. Zetia® (ezetimibe) Tablets [Prescribing Information]. North Wales, PA, Merck/Schering-Plough Pharmaceuticals, 2008.Merck/Schering-Plough PharmaceuticalsZetia® (ezetimibe) Tablets [Prescribing Information].North Wales, PAMerck/Schering-Plough Pharmaceuticals200832.McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584–1587.McKenneyJM]]FarnierM]]LoKW&etal;Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.J Am Coll Cardiol2006471584-158733.Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779–790.BaysH]]DujovneCColesevelam HCl: a non-systemic lipid-altering drug.Expert Opin Pharmacother20034779-79034.Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625–630.PaoliniJF]]MitchelYB]]ReyesR&etal;Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.Am J Cardiol2008101625-63035.Bays H, Davidson MH, Stein EA, et al. Efficacy and safety of micronized fenofibrate-130 mg taken with or without food versus placebo in patients with hypertriglyceridemia and metabolic syndrome—TRIMS study (Triglyceride Reduction in Metabolic Syndrome) [abstract 750]. Endocr Pract 2005;11(Suppl 1):35.BaysH]]DavidsonMH]]SteinEA&etal;Efficacy and safety of micronized fenofibrate-130 mg taken with or without food versus placebo in patients with hypertriglyceridemia and metabolic syndrome—TRIMS study (Triglyceride Reduction in Metabolic Syndrome) [abstract 750].Endocr Pract2005113536.Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C–43C.BaysHESafety considerations with omega-3 fatty acid therapy.Am J Cardiol20079935C-43C37.GlaxoSmithKline. Lovaza® (Omega-3-Acid Ethyl Esters) Capsules [Prescribing Information]. Research Triangle Park, NC, GlaxoSmithKline, 2008.38.Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008;102:429–433.MakiKC]]McKenneyJM]]ReevesMS&etal;Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.Am J Cardiol2008102429-43339.Maki KC, Lubin BC, Reeves MS, et al. Prescription omega-3 acid ethyl esters plus simvastation. J Clin Lipid 2009;33–38.MakiKC]]LubinBC]]ReevesMS&etal;Prescription omega-3 acid ethyl esters plus simvastation.J Clin Lipid2009&NA;33-3840.Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387–393.HarrisWS]]BulchandaniDWhy do omega-3 fatty acids lower serum triglycerides?Curr Opin Lipidol200617387-39341.Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455–463.ParkY]]HarrisWSOmega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance.J Lipid Res200344455-46342.Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12–24.HarrisWS]]MillerM]]TigheAP&etal;Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.Atherosclerosis200819712-2443.Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008;6:391–409.BaysHE]]TigheAP]]SadovskyR&etal;Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.Expert Rev Cardiovasc Ther20086391-40944.Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98:71i–76i.BaysHClinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.Am J Cardiol20069871i-76i45.Oscient Pharmaceuticals. Antara® (fenofibrate) Capsules [Prescribing Information]. Waltham, MA, Oscient Pharmaceuticals, 2006.Oscient PharmaceuticalsAntara® (fenofibrate) Capsules [Prescribing Information].Waltham, MAOscient Pharmaceuticals200646.Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007;99:44C–46C.HarrisWSExpert opinion: omega-3 fatty acids and bleeding-cause for concern?Am J Cardiol20079944C-46C